Literature DB >> 19343296

Targeted therapy and hematological malignancy.

James O Armitage.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19343296     DOI： 10.1007/s11523-008-0098-1

Source DB:  PubMed          Journal:  Target Oncol        ISSN： 1776-2596            Impact factor:   4.493


× No keyword cloud information.
  8 in total

1.  Paul Ehrlich (1854-1915): founder of chemotherapy and pioneer of haematology, immunology and oncology.

Authors:  G Androutsos
Journal:  J BUON       Date:  2004 Oct-Dec       Impact factor: 2.533

2.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

Authors:  Bertrand Coiffier; Eric Lepage; Josette Briere; Raoul Herbrecht; Hervé Tilly; Reda Bouabdallah; Pierre Morel; Eric Van Den Neste; Gilles Salles; Philippe Gaulard; Felix Reyes; Pierre Lederlin; Christian Gisselbrecht
Journal:  N Engl J Med       Date:  2002-01-24       Impact factor: 91.245

Review 3.  The ninth annual David Karnofsky Lecture. Treatment of acute lymphocytic leukemia.

Authors:  D Pinkel
Journal:  Cancer       Date:  1979-03       Impact factor: 6.860

4.  Combination sequential chemotherapy in advanced reticulum cell sarcoma.

Authors:  M Levitt; J C Marsh; R C DeConti; M S Mitchell; R T Skeel; L R Farber; J R Bertino
Journal:  Cancer       Date:  1972-03       Impact factor: 6.860

Review 5.  Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma.

Authors:  Richard J Klasa
Journal:  Oncology (Williston Park)       Date:  2004-11       Impact factor: 2.990

6.  Advanced diffuse histiocytic lymphoma, a potentially curable disease.

Authors:  V T DeVita; G P Canellos; B Chabner; P Schein; S P Hubbard; R C Young
Journal:  Lancet       Date:  1975-02-01       Impact factor: 79.321

7.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

Authors:  P Feugier; A Van Hoof; C Sebban; P Solal-Celigny; R Bouabdallah; C Fermé; B Christian; E Lepage; H Tilly; F Morschhauser; P Gaulard; G Salles; A Bosly; C Gisselbrecht; F Reyes; B Coiffier
Journal:  J Clin Oncol       Date:  2005-05-02       Impact factor: 44.544

8.  Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute.

Authors:  V T DeVita; R M Simon; S M Hubbard; R C Young; C W Berard; J H Moxley; E Frei; P P Carbone; G P Canellos
Journal:  Ann Intern Med       Date:  1980-05       Impact factor: 25.391
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.